Journal
METABOLIC ENGINEERING
Volume 20, Issue -, Pages 29-41Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymben.2013.08.004
Keywords
Tryptophan; Pathway deregulation; Chorismate; Fed-batch; Chromobacterium violaceum; Janthinobacterium lividum
Categories
Funding
- Deutsche Akademische Austauschdienst [A/08/71658]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Max-Buchner Foundation of the DECHEMA [KZ2924]
- Graduate School MINAS - Microbial Natural Products
- regional government of Lower Saxony in Germany
- German Ministry of Science and Education (BMBF) [CHORUS 0312688]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq, Brazil
Ask authors/readers for more resources
Violacein and deoxyviolacein are interesting therapeutics against pathogenic bacteria and viruses as well as tumor cells. In the present work, systems-wide metabolic engineering was applied to target Escherichia coli, a widely accepted recombinant host in pharmaceutical biotechnology, for production of these high-value products. The basic producer, E coli dVio-1, that expressed the vioABCE cluster from Chromobacterium violaceum under control of the inducible araC system, accumulated 180 mg L-1 of deoxyviolacein. Targeted intracellular metabolite analysis then identified bottlenecks in tryptophan supporting pathways, the major product building block This was used for comprehensive engineering of serine, chorismate and tryptophan biosynthesis and the non-oxidative pentose-phosphate pathway. The final strain, E coli dVio-6, accumulated 320 mg L-1 deoxyviolacein in shake flask cultures. The created chassis of a high-flux tryptophan pathway was complemented by genomic integration of the vioD gene of Janthinobacterium lividum, which enabled exclusive production of violacein. In a fed-batch process, the resulting producer E coli Vio-4 accumulated 710 mg L-1 of the desired product. With straightforward broth extraction and subsequent crystallization, violacein could be obtained with 99.8% purity. This demonstrates the potential of E. coli as a platform for production of tryptophan based therapeutics. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available